HEALTH

Aethlon Medical, Inc. (OTCMKTS:AEMD) Given the Go-Ahead for Treating Ebola

Aethlon Medical, Inc. (OTCMKTS:AEMD) is a company known in the stock market for closing in red for most days of the year. However, the fortunes of the company seem to be changing, since after the FDA approved to treat Ebola infected people in the US with the Aethlon Hemopurifier. The stock moved up steadily from a low $0.10 to $0.72. Since then the stock value of the company has been under close watch by stock traders and has been fluctuating.

Even though the company can be a gamble for stock traders, but it has a strong backing from government contracts. Even after the final quarterly report for 2014 showed a net loss of $1.66 million, the company still has enough to carry out its operations in the near future. Additionally, with their new Hemopurifier, the company is expected to make a lot of profits, especially from the Ebola threat in the US. The Aethlon hemopurifier is a bio-filtration device that reduces the number of viral pathogens in the blood.

The company has also been issuing discounted shares in recent months, which have been about 83% lower in price than the current ticker value. 16 million shares were issued at $0.042 in November 2014 alone. This has been followed by another offering of 1.8 million shares at the same price in the Monday filing. Keeping the initial price of the stock low has meant that the value of the stock should remain stable, even if some of the shareholders decide to cash in.

The important thing here, however, is that Aethlon Medical, Inc. (OTCMKTS:AEMD) is a company who just might have a successful cure for the much feared Ebola virus. The company has tested its hemopurifier in Frankfurt, Germany, on a patient suffering from Ebola and had multiple organ failures due to the virus. So with the FDA granting it the permission to treat people in the US, we can expect to see the stock stays on the rise while the traders have a good time.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 traders350.com. All RIGHTS RESERVED.